Compositions comprising bacterial strains
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
1. A pharmaceutical composition that comprises from about 1×10 3 to about 1×10 11 CFU/g of a bacteria strain of the species Eubacterium contortum with respect to total weight of the pharmaceutical composition, and a pharmaceutically acceptable excipient, diluent, or carrier,
wherein the bacteria strain is lyophilized, and wherein the bacteria strain comprises a 16S rRNA gene polynucleotide, wherein the 16S rRNA gene polynucleotide comprises a polynucleotide sequence with at least 99% sequence identity to the polynucleotide sequence of SEQ ID NO:4, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62.
2. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable excipient, diluent, or carrier comprises a lyoprotectant.
3. The pharmaceutical composition of claim 1 , wherein the 16S rRNA gene polynucleotide comprises a polynucleotide sequence with at least 99.5% sequence identity to the polynucleotide sequence of SEQ ID NO:4, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a BLOSUM of 62.
4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises from about 1×10 6 to about 1×10 11 CFU/g of the bacteria strain with respect to total weight of the pharmaceutical composition.
5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral delivery, and wherein the pharmaceutical composition further comprises an enteric coating.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises an adjuvant.
7. The pharmaceutical composition of claim 1 , wherein the 16S rRNA gene polynucleotide comprises a polynucleotide sequence that is the polynucleotide sequence of SEQ ID NO:4.
8. The pharmaceutical composition of claim 1 , wherein the bacteria strain is strain MRX050 deposited with the NCIMB under accession number NCIMB 42689.
9. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises only a de minimis amount of other bacteria strains.
10. The pharmaceutical composition of claim 1 , wherein the composition does not contain any other bacteria strain.
11. A pharmaceutical composition that comprises a bacteria strain of the species Eubacterium contortum and a pharmaceutically acceptable excipient, diluent, or carrier,
wherein the bacteria strain is lyophilized, and wherein the bacteria strain comprises a 16S rRNA gene polynucleotide, wherein the 16S rRNA gene polynucleotide comprises a polynucleotide sequence that is the polynucleotide sequence of SEQ ID NO:4.
12. A pharmaceutical composition that comprises a bacteria strain of the species Eubacterium contortum and a pharmaceutically acceptable excipient, diluent, or carrier,
wherein the bacteria strain is lyophilized, and wherein the bacteria strain is strain MRX050 deposited with the NCIMB under accession number NCIMB 42689.